

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/585,820	06/01/2000	Thomas J. Mercolono	CDS-221	4698
75	590 06/18/2002			
Audley A Cia		EXAMINER		
One Johnson & New Brunswick		GRUN, JAMES LESLIE		
			ART UNIT	PAPER NUMBER
			1641	10
			DATE MAILED: 06/18/2002	2

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/585,820**

Applicant(s)

MERCOLINO et al.

Examiner

James L. Grun, Ph.D.

Art Unit 1641



	The MAILING DATE of this communication appears o	n the	cover sh	et with	the c rrespondence address	
	for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.			XPIRE	3	_ MONTH(S) FROM	
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the						
- If the p - If NO p - Failure - Any re	I date of this communication. beriod for reply specified above is less than thirty (30) days, a reply within the beriod for reply is specified above, the maximum statutory period will apply ar to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of th patent term adjustment. See 37 CFR 1.704(b).	nd will e applic	expire SIX (6) ation to becor	MONTHS f ne ABAND	rom the mailing date of this communication. ONED (35 U.S.C. § 133).	
Status						
1) 💢	Responsive to communication(s) filed on 22 Apr 20	02			•	
2a) 🗌	This action is FINAL . 2b) ☑ This action	on is	non-final			
3) 🗌	Since this application is in condition for allowance exclosed in accordance with the practice under <i>Ex par</i>					
Disposi	tion of Claims					
4) 💢	Claim(s) 16, 20, 22, 23, and 25-51				is/are pending in the application.	
4	la) Of the above, claim(s)				is/are withdrawn from consideration.	
5) 🗆	Claim(s)				is/are allowed.	
6) 💢	Claim(s) 16, 20, 22, 23, and 25-51				is/are rejected.	
7) 🗆	Claim(s)				is/are objected to.	
8) 🗆	Claims		are	subject	to restriction and/or election requirement.	
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)□	The drawing(s) filed on is/are	a) 🗆	accepte	d or b)	\square objected to by the Examiner.	
	Applicant may not request that any objection to the dr	awin	g(s) be he	ld in abe	eyance. See 37 CFR 1.85(a).	
11)□	The proposed drawing correction filed on		is:	a) 🗌 a	approved b) \square disapproved by the Examiner.	
	If approved, corrected drawings are required in reply to	o this	Office ac	tion.		
12)	The oath or declaration is objected to by the Examin	ner.				
•	under 35 U.S.C. §§ 119 and 120					
13)	Acknowledgement is made of a claim for foreign pr	iority	under 35	U.S.C.	§ 119(a)-(d) or (f).	
a)[☐ All b)☐ Some* c)☐ None of:					
	1. Certified copies of the priority documents have					
	2. Certified copies of the priority documents have					
	 Copies of the certified copies of the priority do application from the International Burea ee the attached detailed Office action for a list of the 	au (Pi	CT Rule 1	7.2(a)).		
	Acknowledgement is made of a claim for domestic					
_	The translation of the foreign language provisiona		•			
	Acknowledgement is made of a claim for domestic					
Attachm			,			
_	otice of References Cited (PTO-892)	4)	Interview Su	mmary (PT	O-413) Paper No(s)	
2) 🗌 No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5)	Notice of Inf	ormal Pater	nt Application (PTO-152)	
3) 🗌 In	formation Disclosure Statement(s) (PTO-1449) Paper No(s)	6)	Other:			

Art Unit: 1641

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Technology Center 1600, Group 1640, Art Unit 1641.

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 22 April 2002 has been entered.

Claims 29-51 are newly added. Claims 1-15, 17-19, 21, and 24 have been cancelled. Claims 16, 20, 22, 23, and 25-51 remain in the case.

Applicant is now required to submit acceptable corrected drawings within the time period set in the Office action. See 37 CFR 1.85(a). Submission of corrected drawings may no longer be held in abeyance pending the indication of allowable subject matter. Failure to take corrective action within the set period will result in **ABANDONMENT** of the application.

Claims 16, 20, 22, 23, and 25-51 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1641

Claims 16, 20, 29, 22, 23, and 49 positively claim identical subject matter as claimed in claims 25, 26, 30, 27, 28, and 50, respectively, and differ only in the intended use recitations of their preambles, recitations which do not serve to distinguish the same subject matter from itself. In these claims it is not clear what is encompassed or excluded by "in a single test" because a single test may be a multi-vessel technology.

In claims 25-28, 30, and 50, it is not clear what is being determined because the relationship of the cell populations to reverse ABO typing is not clear as reverse ABO typing is accepted as determining antibodies not cell populations.

In claims 31-35 and 51, it is not clear what is being determined because the relationships of antibody testing to the cell populations and to reverse ABO type are not clear. In these claims it is not clear what is encompassed or excluded by "in a single test" because a single test may be a multi-vessel technology.

In claims 36-41 the interrelationships of the steps and components are not clear, for example because: the relationship of antibody to sample or admixture is not clear; the relationship of antibody to first or second antigen or to agglutinate is not clear; the relationship of screen to detecting and identifying is not clear. In these claims it is not clear what is encompassed or excluded by "in a single test" because a single test may be a multi-vessel technology.

In claims 42-45, "the populations" and "the antibody" lack antecedent basis.

In claims 46-48, recitation of "the populations" lacks antecedent basis.

Art Unit: 1641

Claims 42-44 and 46-47 are rejected under 35 U.S.C. § 102(b) as being clearly anticipated by Ullman (U.S. Pat. No. 4,584,277) for reasons of record in the prior rejection of the similar subject matter of claims 8-11.

As set forth, Ullman teaches fluorescently labelled anti-blood group antigen antibodies and fluorescently labelled erythrocytes having blood group antigens thereon added simultaneously or sequentially to a sample of whole blood for multiparameter analysis of ABO blood type and isoantibodies (i.e. reverse blood typing) (see e.g. col. 3-4). A variety of combinations of parameters and suitable reagents are taught (see e.g. col. 3, Table 1). Suitable fluorescent labels are taught (e.g. col. 8-9). The reagents of the reference clearly anticipate those as instantly claimed.

Claims 16, 20, 22, 25-27, 29-34, 36-40, and 49-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Yves [Lapierre] et al (U.S. Pat. No. 5,338,689) for reasons of record in the prior rejection of the similar subject matter of claims 16, 20, 22, and 25-27. The examiner notes that "a single test" as instantly claimed may be a multi-vessel technology.

Claims 16, 20, 22, 25-27, 29-34, 36-40, and 49-51 are rejected under 35 U.S.C. 102(b) as being anticipated by Chachowski et al (U.S. Pat. No. 5,552,064) for reasons of record in the prior rejection of the similar subject matter of claims 16, 20, 22, and 25-27. The examiner notes that "a single test" as instantly claimed may be a multi-vessel technology.

Art Unit: 1641

Claims 16, 20, 22, 23, and 25-51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chachowski et al (U.S. Pat. No. 5,552,064) in view of Shen et al (U.S. Pat. No. 5,594,808) for reasons of record in the prior rejection of the similar subject matter of claims 16, 20, 22, 23, and 25-28.

Applicant's arguments filed 22 April 2002 have been fully considered but they are not deemed to be persuasive.

In response to applicant's argument that the references of Yves [Lapierre] et al (U.S. Pat. No. 5,338,689), alone, or Chachowski et al (U.S. Pat. No. 5,552,064), alone or as modified, fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e.: erythrocytes stained with a dye to alter the color of one cell population; two distinct cell populations agglutinating in a single reaction vessel) are not recited in the claim(s) rejected over these references. Applicant's attention is again drawn to the vague recitation of "in a single test" noted previously in this Office action. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Art Unit: 1641

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

The disclosure of Ullman (U.S. Pat. No. 4,713,348) is essentially identical to the disclosure of Ullman (U.S. Pat. No. 4,584,277).

Vorpahl et al (U.S. Pat. No. 5,071,774) teach that determination of the agglutination of two sets of red blood cells can be used for determination of the presence of an agglutinating agent for one or both of the red blood cell sets (see e.g. col. 9). As in Ullman (U.S. Pat. No. 4,584,277), combined addition of means for separately agglutinating two sets of red blood cells (e.g., anti-blood group antigen antibodies) along with the two sets of erythrocytes (e.g. erythrocytes having blood group antigens thereon), at least one of the sets being labelled with a fluorophore such that the sets are separately detectable and distinguishable, to a sample is used in the method.

Chang et al (U.S. Pat. No. 4,748,129) teach the addition of a fluorescent agent capable of incorporation into a cell as a means of labelling erythrocytes for agglutination assays. Suitable fluorescent agents are taught (e.g. col. 4-7).

Vyas et al (U.S. Pat. No. 5,776,711) teach a simultaneous blood typing/antibody screening method using flow cytometry.

Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James L. Grun, Ph.D., whose telephone number is (703) 308-3980. The examiner can normally be reached on weekdays from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, SPE, can be contacted at (703) 305-3399.

The phone numbers for official facsimile transmitted communications to TC 1600, Group 1640, are (703) 872-9306, or (703) 305-3014, or (703) 308-4242. Official After Final communications, only, can be facsimile transmitted to (703) 872-9307.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196. The above inquiries, or requests to supply missing elements from Office communications, can also be directed to the TC 1600 Customer Service Office at phone numbers (703) 308-0197 or (703) 308-0198.

James L. Grun, Ph.D.

June 14, 2002

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800/69/

Christyl L. Chi